Zealand University Hospital
Welcome,         Profile    Billing    Logout  
 79 Trials 
54 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gögenur, Ismail
MEFO, NCT04312360: Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (-trial)

Completed
2
28
Europe
therapeutic endoscopy with metronidazole and fosfomycin disodium
Zealand University Hospital, Costerton Biofilm Center, Reponex Pharmaceuticals A/S, Region Zealand
Right-sided Colon Cancer, Right-sided Colon Adenoma
04/22
07/23
Kelbæk, Henning
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
12/23
06/27
BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting
N/A
200
Europe
Lithoplasty, Shockwave, Lithotripsy, Conventional
Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
09/24
01/25
Pedersen, Lars
BELIEF, NCT06631937: HMOs on Infant Gut Microbiota Modulation and Development of the Immune System in Healthy Infants

Recruiting
N/A
334
Europe
Human Milk Oligosaccharides, Placebo
University of Aarhus, University of Copenhagen, Technical University of Denmark, Chr Hansen
Healthy Infants
12/26
08/27
Hansen, Ditte
PRIMETIME WP2, NCT04916132: Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Recruiting
N/A
300
Europe
Kidney Biopsy
Herlev Hospital, Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy
12/43
12/43
Gehl, Julie
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
Contact, Use Central
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
PAT-CHINA-303, NCT05136664: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Recruiting
3
290
RoW
Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B)
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Hyperkalemia, Renal Insufficiency, Chronic
07/25
09/25
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Active, not recruiting
3
136
US
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo
CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Graft Versus Host Disease (GVHD)
06/24
05/25
RECLAIIM, NCT04044690 / 2018-003171-35: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Terminated
3
126
Europe, Japan, US, RoW
human immunoglobulin G, IgPro20, Hizentra, Placebo
CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
Dermatomyositis
12/24
12/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Active, not recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
12/25
12/25
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Recruiting
3
35
Canada, US, RoW
CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec
CSL Behring
Hemophilia B
10/28
10/28
NCT06699849: Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Recruiting
2/3
260
US
CSL889, Hemopexin, human, Placebo
CSL Behring
Sickle Cell Disease Vaso-occlusive Crisis
04/28
04/28
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Recruiting
2/3
310
Europe, Japan, US, RoW
AAT, Alpha-1 proteinase inhibitor, Respreeza, Placebo
CSL Behring, Commercial/Industry, CSL
Acute-graft-versus-host Disease
04/28
10/29
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Active, not recruiting
2
81
Europe, RoW
Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL
Astellas Pharma Europe Ltd.
Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation
10/15
12/25
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting
2
38
US
TARA-002
Protara Therapeutics
Lymphatic Malformation
12/25
05/26
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Recruiting
2
127
Canada, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
05/30
08/30
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Terminated
1
52
Europe
CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo
CSL Behring
Immune Complex-mediated Autoimmune Diseases
03/23
03/23
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge

Completed
1
40
Europe
CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo
CSL Behring
Healthy Volunteers
07/23
07/23
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed
1
10
US
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
09/24
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed
1
12
Europe, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
10/24
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Recruiting
1
60
RoW
CSL040, Placebo
CSL Behring
Disease Driven by Complement Activation
04/25
04/25
THRIVE-1, NCT05011370: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
N/A
80
Europe, US
Protara Therapeutics
Intestinal Failure-associated Liver Disease
06/23
06/23
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting
N/A
500
US
HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX)
CSL Behring
Hemophilia B
08/43
08/43
Hansen, Lars B
NCT06100289: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Recruiting
3
70
Europe, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002, Vedolizumab SC, MLN0002SC
Takeda
Ulcerative Colitis, Crohn's Disease
06/27
06/27
ICEBERG, NCT04857580: Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture

Withdrawn
N/A
45
Europe
CTS Device
Cryotherapeutics SA
Acute Coronary Syndrome
12/22
12/22
Kjær, Troels
ULTS, NCT04513743: Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ

Completed
N/A
25
Europe
24/7 EEG™ SubQ
UNEEG Medical A/S, Zealand University Hospital, Cambridge Cognition Ltd
Sleep
06/22
07/22
AD-LBD-EPI, NCT04436341: Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia

Completed
N/A
50
Europe
Danish Dementia Research Centre, Zealand University Hospital, Rigshospitalet, Denmark, University of Aarhus, T&W Engineering A/S
Alzheimer Disease, Lewy Body Disease, Epilepsy
09/22
06/23
Azawi, Nessn H
NCT05626686: An Exploratory Investigation of the Effects of Single Use vs. Reuse Catheters in Intermittent Catheterization

Completed
N/A
40
Europe
CLINY catheter
Coloplast A/S
Urinary Incontinence
03/23
03/23
GaGnostic, NCT05060783: Renal Cancer Detection With Liquid Biopsy

Recruiting
N/A
200
Europe
GaGnostic, Glycosaminoglycan
Zealand University Hospital, Lund University, Elypta
Renal Cancer, Oncocytoma
07/25
07/27
AUR93A, NCT05028660: AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

Completed
N/A
43
Europe
GAG score
Elypta, Lund University
Muscle-Invasive Bladder Carcinoma
04/25
04/25
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Completed
N/A
280
Europe, Canada, US
GAG score
Elypta
Clear Cell Renal Cell Carcinoma
05/25
05/25
Rose, Michael
iAccelerate, NCT05329584: InSpace Accelerated Rehabilitation Study

Recruiting
N/A
160
US
InSpace Subacromial Tissue Spacer
Stryker Endoscopy
Rotator Cuff Tears
04/26
12/26
SECURE, NCT04537013: Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee

Active, not recruiting
N/A
234
Europe, Canada, US
Microfracture, Microfracture plus placement of Chondro-Gide® ACC
Geistlich Pharma AG, Telos Partners
Knee Injuries, Cartilage Injury, Cartilage Disease, Knee Discomfort
12/26
12/28
Veien, Karsten
BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting
N/A
200
Europe
Lithoplasty, Shockwave, Lithotripsy, Conventional
Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
09/24
01/25
Lindhardt, Morten
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
16700
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
PRIMETIME WP2, NCT04916132: Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Recruiting
N/A
300
Europe
Kidney Biopsy
Herlev Hospital, Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy
12/43
12/43
Wiese, Lothar
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Completed
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIVr, licensed aQIV
Seqirus
Influenza, Human
03/24
01/25
Høgh, Peter
NCT05260177: Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Recruiting
N/A
62
Europe
Light Therapy System (LTS): Active Setting, Light Therapy System (LTS): Sham Setting
Zealand University Hospital, OptoCeutics, University of Copenhagen, Technical University of Denmark, Göteborg University
Alzheimer's Disease
05/25
12/26
Borg, Rikke
PRIMETIME WP2, NCT04916132: Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Recruiting
N/A
300
Europe
Kidney Biopsy
Herlev Hospital, Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy
12/43
12/43
Poulsen, Christian B
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
Gliese, Kirstine
Elixir, NCT03994471 / 2019-004183-21: Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Recruiting
3
170
Europe
XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, XyloCore 0.7 or 1.5 or 2.0, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution, Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance
Iperboreal Pharma Srl, Iperboreal Pharma Srl,
End Stage Renal Disease
12/25
04/26
Vásquez, Juan Luis
NCT05223491: En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

Recruiting
N/A
220
Europe
En Bloc resection, Conventional TURB
Jørgen Bjerggaard Jensen, University of Aarhus, Novo Nordisk A/S
Non-muscle Invasive Bladder Cancer
12/24
12/26
Horning, Maibritt
NCT05260177: Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Recruiting
N/A
62
Europe
Light Therapy System (LTS): Active Setting, Light Therapy System (LTS): Sham Setting
Zealand University Hospital, OptoCeutics, University of Copenhagen, Technical University of Denmark, Göteborg University
Alzheimer's Disease
05/25
12/26
Agger, Mikkel Pejstrup
NCT05260177: Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Recruiting
N/A
62
Europe
Light Therapy System (LTS): Active Setting, Light Therapy System (LTS): Sham Setting
Zealand University Hospital, OptoCeutics, University of Copenhagen, Technical University of Denmark, Göteborg University
Alzheimer's Disease
05/25
12/26
Falk, Mads
No trials found
Justesen, Tobias F
No trials found
Kristensen-Alvarez, Anna
No trials found
Clausen, Tove
No trials found
Larsen, Line G
No trials found
Andersson, Mette
No trials found
Al-Mousawi, Ali
No trials found
Krapper, Anne-Dorte b
No trials found
Bodilsen, Stefan S
No trials found
Lønkvist, Camilla
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gögenur, Ismail
MEFO, NCT04312360: Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (-trial)

Completed
2
28
Europe
therapeutic endoscopy with metronidazole and fosfomycin disodium
Zealand University Hospital, Costerton Biofilm Center, Reponex Pharmaceuticals A/S, Region Zealand
Right-sided Colon Cancer, Right-sided Colon Adenoma
04/22
07/23
Kelbæk, Henning
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
12/23
06/27
BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting
N/A
200
Europe
Lithoplasty, Shockwave, Lithotripsy, Conventional
Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
09/24
01/25
Pedersen, Lars
BELIEF, NCT06631937: HMOs on Infant Gut Microbiota Modulation and Development of the Immune System in Healthy Infants

Recruiting
N/A
334
Europe
Human Milk Oligosaccharides, Placebo
University of Aarhus, University of Copenhagen, Technical University of Denmark, Chr Hansen
Healthy Infants
12/26
08/27
Hansen, Ditte
PRIMETIME WP2, NCT04916132: Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Recruiting
N/A
300
Europe
Kidney Biopsy
Herlev Hospital, Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy
12/43
12/43
Gehl, Julie
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
Contact, Use Central
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
PAT-CHINA-303, NCT05136664: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Recruiting
3
290
RoW
Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B)
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Hyperkalemia, Renal Insufficiency, Chronic
07/25
09/25
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Active, not recruiting
3
136
US
Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo
CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Graft Versus Host Disease (GVHD)
06/24
05/25
RECLAIIM, NCT04044690 / 2018-003171-35: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Terminated
3
126
Europe, Japan, US, RoW
human immunoglobulin G, IgPro20, Hizentra, Placebo
CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
Dermatomyositis
12/24
12/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Active, not recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Active, not recruiting
3
20
Europe, Canada, US, RoW
CSL312, Garadacimab
CSL Behring
Hereditary Angioedema (HAE)
12/25
12/25
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Recruiting
3
35
Canada, US, RoW
CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec
CSL Behring
Hemophilia B
10/28
10/28
NCT06699849: Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Recruiting
2/3
260
US
CSL889, Hemopexin, human, Placebo
CSL Behring
Sickle Cell Disease Vaso-occlusive Crisis
04/28
04/28
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Recruiting
2/3
310
Europe, Japan, US, RoW
AAT, Alpha-1 proteinase inhibitor, Respreeza, Placebo
CSL Behring, Commercial/Industry, CSL
Acute-graft-versus-host Disease
04/28
10/29
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Active, not recruiting
2
81
Europe, RoW
Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL
Astellas Pharma Europe Ltd.
Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation
10/15
12/25
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Recruiting
2
38
US
TARA-002
Protara Therapeutics
Lymphatic Malformation
12/25
05/26
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Recruiting
2
127
Canada, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
05/30
08/30
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Terminated
1
52
Europe
CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo
CSL Behring
Immune Complex-mediated Autoimmune Diseases
03/23
03/23
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge

Completed
1
40
Europe
CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo
CSL Behring
Healthy Volunteers
07/23
07/23
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed
1
10
US
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
09/24
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed
1
12
Europe, US, RoW
TARA-002
Protara Therapeutics
Non-muscle Invasive Bladder Cancer
09/24
10/24
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Recruiting
1
60
RoW
CSL040, Placebo
CSL Behring
Disease Driven by Complement Activation
04/25
04/25
THRIVE-1, NCT05011370: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
N/A
80
Europe, US
Protara Therapeutics
Intestinal Failure-associated Liver Disease
06/23
06/23
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting
N/A
500
US
HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX)
CSL Behring
Hemophilia B
08/43
08/43
Hansen, Lars B
NCT06100289: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Recruiting
3
70
Europe, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002, Vedolizumab SC, MLN0002SC
Takeda
Ulcerative Colitis, Crohn's Disease
06/27
06/27
ICEBERG, NCT04857580: Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture

Withdrawn
N/A
45
Europe
CTS Device
Cryotherapeutics SA
Acute Coronary Syndrome
12/22
12/22
Kjær, Troels
ULTS, NCT04513743: Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ

Completed
N/A
25
Europe
24/7 EEG™ SubQ
UNEEG Medical A/S, Zealand University Hospital, Cambridge Cognition Ltd
Sleep
06/22
07/22
AD-LBD-EPI, NCT04436341: Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia

Completed
N/A
50
Europe
Danish Dementia Research Centre, Zealand University Hospital, Rigshospitalet, Denmark, University of Aarhus, T&W Engineering A/S
Alzheimer Disease, Lewy Body Disease, Epilepsy
09/22
06/23
Azawi, Nessn H
NCT05626686: An Exploratory Investigation of the Effects of Single Use vs. Reuse Catheters in Intermittent Catheterization

Completed
N/A
40
Europe
CLINY catheter
Coloplast A/S
Urinary Incontinence
03/23
03/23
GaGnostic, NCT05060783: Renal Cancer Detection With Liquid Biopsy

Recruiting
N/A
200
Europe
GaGnostic, Glycosaminoglycan
Zealand University Hospital, Lund University, Elypta
Renal Cancer, Oncocytoma
07/25
07/27
AUR93A, NCT05028660: AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

Completed
N/A
43
Europe
GAG score
Elypta, Lund University
Muscle-Invasive Bladder Carcinoma
04/25
04/25
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Completed
N/A
280
Europe, Canada, US
GAG score
Elypta
Clear Cell Renal Cell Carcinoma
05/25
05/25
Rose, Michael
iAccelerate, NCT05329584: InSpace Accelerated Rehabilitation Study

Recruiting
N/A
160
US
InSpace Subacromial Tissue Spacer
Stryker Endoscopy
Rotator Cuff Tears
04/26
12/26
SECURE, NCT04537013: Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee

Active, not recruiting
N/A
234
Europe, Canada, US
Microfracture, Microfracture plus placement of Chondro-Gide® ACC
Geistlich Pharma AG, Telos Partners
Knee Injuries, Cartilage Injury, Cartilage Disease, Knee Discomfort
12/26
12/28
Veien, Karsten
BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting
N/A
200
Europe
Lithoplasty, Shockwave, Lithotripsy, Conventional
Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
09/24
01/25
Lindhardt, Morten
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
16700
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
PRIMETIME WP2, NCT04916132: Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Recruiting
N/A
300
Europe
Kidney Biopsy
Herlev Hospital, Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy
12/43
12/43
Wiese, Lothar
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Completed
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIVr, licensed aQIV
Seqirus
Influenza, Human
03/24
01/25
Høgh, Peter
NCT05260177: Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Recruiting
N/A
62
Europe
Light Therapy System (LTS): Active Setting, Light Therapy System (LTS): Sham Setting
Zealand University Hospital, OptoCeutics, University of Copenhagen, Technical University of Denmark, Göteborg University
Alzheimer's Disease
05/25
12/26
Borg, Rikke
PRIMETIME WP2, NCT04916132: Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Recruiting
N/A
300
Europe
Kidney Biopsy
Herlev Hospital, Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy
12/43
12/43
Poulsen, Christian B
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
Gliese, Kirstine
Elixir, NCT03994471 / 2019-004183-21: Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Recruiting
3
170
Europe
XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, XyloCore 0.7 or 1.5 or 2.0, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution, Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance
Iperboreal Pharma Srl, Iperboreal Pharma Srl,
End Stage Renal Disease
12/25
04/26
Vásquez, Juan Luis
NCT05223491: En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

Recruiting
N/A
220
Europe
En Bloc resection, Conventional TURB
Jørgen Bjerggaard Jensen, University of Aarhus, Novo Nordisk A/S
Non-muscle Invasive Bladder Cancer
12/24
12/26
Horning, Maibritt
NCT05260177: Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Recruiting
N/A
62
Europe
Light Therapy System (LTS): Active Setting, Light Therapy System (LTS): Sham Setting
Zealand University Hospital, OptoCeutics, University of Copenhagen, Technical University of Denmark, Göteborg University
Alzheimer's Disease
05/25
12/26
Agger, Mikkel Pejstrup
NCT05260177: Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Recruiting
N/A
62
Europe
Light Therapy System (LTS): Active Setting, Light Therapy System (LTS): Sham Setting
Zealand University Hospital, OptoCeutics, University of Copenhagen, Technical University of Denmark, Göteborg University
Alzheimer's Disease
05/25
12/26
Falk, Mads
No trials found
Justesen, Tobias F
No trials found
Kristensen-Alvarez, Anna
No trials found
Clausen, Tove
No trials found
Larsen, Line G
No trials found
Andersson, Mette
No trials found
Al-Mousawi, Ali
No trials found
Krapper, Anne-Dorte b
No trials found
Bodilsen, Stefan S
No trials found
Lønkvist, Camilla
No trials found

Download Options